A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children
NCT01198756
Completed
This study is designed to test the immunogenicity and safety of an investigational influenza vaccine, in children compared to two other influenza vaccines.
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
08/22/2018
Locations: GSK Investigational Site, Chandler, Arizona +32 locations
Conditions: Influenza
Register for Updates
HerpeVac Trial for Young Women
NCT00057330
Completed
The primary purpose of this study is to see if a herpes vaccine may prevent genital herpes disease in women who are not infected. The study will enroll approximately 7550 healthy women. These women will be randomly assigned to 1 of 2 possible study groups: herpes vaccine (experimental group) or hepatitis A vaccine (control group). Participants will receive their assigned vaccine at 0, 1, and 6 months. Participants will have 9 scheduled study visits and additional unscheduled visits for an evalua... Read More
Gender:
FEMALE
Ages:
Between 18 years and 30 years
Trial Updated:
07/26/2018
Locations: GSK Investigational Site, Birmingham, Alabama +74 locations
Conditions: Herpes Simplex Infection
Register for Updates
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
NCT00122681
Completed
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection often goes away by itself, but if it does not go away (this is called persistent infection), it can lead in women over a long period of time to cancer of the cervix. If a woman is not infected by HPV, it is very unlikely that she will get... Read More
Gender:
FEMALE
Ages:
Between 15 years and 25 years
Trial Updated:
07/02/2018
Locations: GSK Investigational Site, Birmingham, Alabama +137 locations
Conditions: Infections, Papillomavirus
Register for Updates
Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
NCT00541970
Completed
Human Papillomavirus (HPV) infection has been established as a necessary cause of cervical cancer. GlaxoSmithKline (GSK) Biologicals has developed an HPV vaccine (580299) which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18), found in approximately 70% of all cervical cancers. In previous trials this vaccine has been found to be efficacious in the prevention of incident and persistent HPV-16/18 infections and associated cytological abnormalities and cervical dysplasia. In this... Read More
Gender:
FEMALE
Ages:
Between 9 years and 25 years
Trial Updated:
06/28/2018
Locations: GSK Investigational Site, Edmonton, Alberta +24 locations
Conditions: Infections, Papillomavirus
Register for Updates
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
NCT00578227
Completed
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a rational strategy for prevention of cervical cancer, and so HPV vaccination could complement the existing pre-adolescent/adolescent vaccination programs. Therefore, this Phase IIIb study is designed to evaluate the safety and immunogenicity of co-administering a commerc... Read More
Gender:
FEMALE
Ages:
Between 9 years and 15 years
Trial Updated:
06/28/2018
Locations: GSK Investigational Site, Surrey, British Columbia +20 locations
Conditions: Infections, Papillomavirus
Register for Updates
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age
NCT01659086
Completed
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity of different formulations of a two-dose primary series and booster vaccination of monovalent Influenza H9N2 vaccine manufactured in Quebec, Canada with and without adjuvant, in adults 18 to 64 years of age.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/14/2018
Locations: GSK Investigational Site, Miami, Florida +3 locations
Conditions: Influenza
Register for Updates
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
NCT00719043
Completed
The purpose of this study is to determine whether GSK's avian flu vaccine GSK 1557484A is immunogenic and safe when given to adults aged \>=18 years. This Protocol Posting has been updated following Amendments 1-3 of the Protocol, Dec 2009. The impacted sections are study design and outcome measures.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/08/2018
Locations: GSK Investigational Site, Denver, Colorado +12 locations
Conditions: Influenza
Register for Updates
Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America
NCT00546078
Completed
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. This study will further evaluate induction of immune memory and anamnestic responses in women who previously took part in the primary study (580299/001) and follow-up study (580299/007). Subjects were aged 15-25 yrs at the time of entry into the primary study and participation in the follow-up study lasted approximately 6 years. In the primary and follow-up studies, subjects were prote... Read More
Gender:
FEMALE
Ages:
Between 15 years and 25 years
Trial Updated:
05/24/2018
Locations: GSK Investigational Site, San Francisco, California +16 locations
Conditions: Infections, Papillomavirus
Register for Updates
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
NCT01954251
Completed
The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to administration of vaccines separately.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
03/30/2018
Locations: GSK Investigational Site, Phoenix, Arizona +19 locations
Conditions: Herpes Zoster
Register for Updates
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age
NCT01999842
Completed
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/26/2017
Locations: GSK Investigational Site, Jacksonville, Florida +7 locations
Conditions: Influenza
Register for Updates
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines
NCT01905215
Completed
The purpose of this first time in human (FTiH) study is to evaluate the safety, reactogenicity and immunogenicity of several formulations of Respiratory Syncytial Virus (RSV) investigational vaccines in healthy men.
Gender:
MALE
Ages:
Between 18 years and 44 years
Trial Updated:
05/24/2017
Locations: GSK Investigational Site, Halifax, Nova Scotia +2 locations
Conditions: Infections, Respiratory Syncytial Virus
Register for Updates
Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age
NCT01934127
Completed
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 21 to 64 years of age. The study will evaluate safety related events and antibody immune responses to different formulations of study vaccine and placebo.
Gender:
ALL
Ages:
Between 21 years and 64 years
Trial Updated:
05/04/2017
Locations: GSK Investigational Site, Miami, Florida +8 locations
Conditions: Influenza
Register for Updates